Definium Therapeutics, Inc.— Sankey Diagram
Annual mode · period ending 2025-12-31 · SEC EDGAR
FY2023 - Q4(Oct 23 · Nov 23 · Dec 23)
Total Assets
$440M
↑+45.7% +$138Mvs FY2024
Total Liabilities
$108M
↑+77.5% +$47Mvs FY2024
Equity
$332M
↑+37.6% +$91Mvs FY2024
Cash
$258M
↓-5.8% -$16Mvs FY2024
Click a Metric or Sankey Node to View Historical Trends
Show Source Data (Audit Panel)
| Line item | FY2025 | FY2024 |
|---|---|---|
| Total Assets | $440M | $302M |
| Current Assets | $419M | $282M |
| Cash | $258M | $274M |
| ST Investments | $154M | $0 |
| Receivables | $0 | $0 |
| Inventory | $0 | $0 |
| Other Current | $8M | $8M |
| Non-Current Assets | $21M | $21M |
| PPE | $0 | $0 |
| Goodwill | $20M | $20M |
| Intangibles | $0 | $0 |
| Investments | $0 | $0 |
| Other Non-Current | $862K | $613K |
| Total Liab+Eq | $440M | $302M |
| Current Liab. | $67M | $39M |
| Accounts Payable | $5M | $2M |
| Short-Term Debt | $0 | $0 |
| Deferred Revenue | $0 | $0 |
| Other CL | $61M | $37M |
| Non-Current Liab. | $41M | $22M |
| Long-Term Debt | $41M | $22M |
| Other LT Liab. | $496K | $0 |
| Equity | $332M | $241M |
| Retained Earnings | $583M | $399M |
| Other Equity | $0 | $0 |
QuarterCharts · SEC EDGAR data · DFTX · Comparing FY2025 vs FY2024